Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06057935 · ClinicalTrials.gov registry record · Phase 2
A Study of Additional Chemotherapy After Surgery for People With Malignant Peritoneal Mesothelioma
A Phase 2 study of Mesothelioma and Malignant Mesothelioma, sponsored by Memorial Sloan Kettering Cancer Center.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 64
- Enrollment target
- 13
- Study locations
NCT06057935: Recruiting Phase 2 study of Mesothelioma and Malignant Mesothelioma, sponsored by Memorial Sloan Kettering Cancer Center.
NCT06057935 is a Phase 2 study of Mesothelioma and Malignant Mesothelioma that is actively recruiting participants, run by Memorial Sloan Kettering Cancer Center. The registered enrollment target is 64 participants, below the 197-participant average among 46 other Mesothelioma trials with a reported enrollment target (68% lower). The trial reports 13 study locations across 7 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06057935, a Phase 2 study of Mesothelioma and Malignant Mesothelioma, is actively recruiting participants, sponsored by Memorial Sloan Kettering Cancer Center.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 64 participants
- Enrollment target
- 13
- Study locations
Study Summary
The purpose of this study is to find out whether intraperitoneal or intravenous chemotherapy given after cytoreductive surgery and HIPEC are effective treatments for people with malignant peritoneal mesothelioma. Outcomes will be compared by observing intraperitoneal versus intravenous treatments to analyze if one is better than the other.
Primary Outcome
Progression Free Survival in the two treatment arms.
Conditions Studied
Interventions
- DRUG Carboplatin
- DRUG Cisplatin
- DRUG Pemetrexed
Study Locations (13)
New Jersey
- Memorial Sloan Kettering Basking Ridge (Limited Protocol Activities) - Basking Ridge
- Memorial Sloan Kettering Monmouth (Limited Protocol Activities) - Middletown
- Memorial Sloan Kettering Bergen (Limited Protocol Activities) - Montvale
- Rutgers University (Data Collection Only) - New Brunswick
New York
- Memorial Sloan Kettering Commack (Limited Protocol Activities) - Commack
- Memorial Sloan Kettering Westchester (Limited Protocol Activites) - Harrison
- Memorial Sloan Kettering Cancer Center (All Protocol Activities) - New York
- Memorial Sloan Kettering Nassau (Limited Protocol Activities) - Uniondale
Illinois
- University of Chicago (Data Collection Only) - Chicago
Michigan
- University of Michigan (Data Collection Only) - Ann Arbor
Missouri
- Washington University (Data Collection Only) - St Louis
Nebraska
- University of Nebraska (Data collection only) - Omaha
Pennsylvania
- Allegheny Health Network (Data Collection Only) - Pittsburgh
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 64 participants |
| Start Date | 2023-09-21 |
| Est. Completion | 2028-09-21 |
| Phase | Phase 2 |
What NCT06057935 shows while recruiting
NCT06057935 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 64 participants, a relatively small participant target, below the 197-participant average among 46 other Mesothelioma trials with a reported enrollment target (68% lower).
The record links to 5 conditions, with Mesothelioma appearing as the primary indexed condition, and to 3 interventions - of which Carboplatin is the first listed.
NCT06057935 lists 13 locations in 7 states (New Jersey, New York, Illinois).
Frequently Asked Questions
What is clinical trial NCT06057935 about?
NCT06057935 is a clinical study titled "A Study of Additional Chemotherapy After Surgery for People With Malignant Peritoneal Mesothelioma". The purpose of this study is to find out whether intraperitoneal or intravenous chemotherapy given after cytoreductive surgery and HIPEC are effective treatments for people with malignant peritoneal mesothelioma. Outcomes will be compared by observing intraperitoneal versus intravenous treatments to...
What is the current status of trial NCT06057935?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 64 participants. The study started on 2023-09-21. Estimated completion is 2028-09-21.
What conditions does trial NCT06057935 study?
This clinical trial studies the following conditions: Mesothelioma, Malignant Mesothelioma, Mesothelioma, Malignant, Peritoneal Mesothelioma, Malignant Peritoneal Mesothelioma.
What interventions are being tested in trial NCT06057935?
The interventions under investigation include: Carboplatin (DRUG), Cisplatin (DRUG), Pemetrexed (DRUG).
Who is sponsoring clinical trial NCT06057935?
This trial is sponsored by Memorial Sloan Kettering Cancer Center, which has 1,884 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06057935 being conducted?
This trial has 13 study locations across Illinois, Michigan, Missouri, Nebraska, New Jersey. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Mesothelioma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06057935's enrollment target sits among peer trials
64 29th of 46 higher than 18 of 46 other Mesothelioma trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Mesothelioma trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
A Study of Sacituzumab Govitecan in People With Mesothelioma
RECRUITING · Phase 2
-
Olaparib in Patients With HRD Malignant Mesothelioma
RECRUITING · Phase 2
-
Adoptive Transfer of Tumor Infiltrating Lymphocytes for Advanced Solid Cancers
RECRUITING · Phase 2
-
MAGIC AKI: Magnesium for the Prevention of HIOC-Associated AKI
RECRUITING · Phase 2
-
18F-Fibroblast Activation Protein Inhibitor ([18F]FAPI-74) PET Imaging for Cancer Detection
RECRUITING · Phase 2
-
Neoadjuvant Immune Checkpoint Blockade in Resectable Malignant Pleural Mesothelioma
ACTIVE NOT RECRUITING · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01853631 · 64 participants · Phase 1
Activated T-Cells Expressing 2nd or 3rd Generation CD19-Specific CAR, Advanced B-Cell NHL, ALL, and CLL (SAGAN)
- NCT03739502 · 64 participants · Phase 2
A Randomized Phase II Study of Hyperbaric Oxygen in Improving Engraftment in Umbilical Cord Blood Stem Cell Transplant
- NCT03739814 · 64 participants · Phase 2
Inotuzumab Ozogamicin and Blinatumomab With or Without Ponatinib in Treating Patients With Newly Diagnosed, Recurrent, or Refractory CD22-Positive B-Lineage Acute Lymphoblastic Leukemia
- NCT03866408 · 64 participants · Early Phase 1
Insulin Regulation of Lipolysis and Lipolysis Proteins
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI